<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="918">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04352465</url>
  </required_header>
  <id_info>
    <org_study_id>LDE-MTX_COVID19</org_study_id>
    <nct_id>NCT04352465</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients</brief_title>
  <official_title>Treatment of Acute Respiratory Syndrome Resulting From the Inflammatory Process of COVID-19 Infection Using Methotrexate-loaded Nanoparticles: A Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>InCor Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Santa Marcelina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PREVENT SENIOR PRIVATE OPERADORA DE SAÚDE LTDA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azidus Brasil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy and safety of MTX-loaded nanoparticles in
      three different doses to treat severe COVID-19 patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute lung injury caused by COVID-19 disease are experiencing an inflammatory
      reaction that can be harmful and worsen the severity of the clinical condition. Thus, the use
      of MTX-loaded nanoparticules in patients with acute lung injury secondary to COVID-19 aims to
      decrease the exacerbated inflammatory reaction leading to a decrease in cell damage caused by
      this inflammatory process in patients.

      The study will be divided in 3 phases:

      Phase A (n=4): IV administration of 20 mg of MTX-loaded nanoparticles. Four doses of
      Investigational Product (IP) will be administered, once per week. If patients show clinical
      improvement after 2nd or 3rd administration, the next phase will start.

      Phase B (n=12): IV administration of 30 mg of MTX-loaded nanoparticles. Four doses of
      Investigational Product (IP) will be administered, once per week. If patients show clinical
      improvement after 2nd or 3rd administration, the next phase will start.

      Fase C (n=26): IV administration of 40 mg of MTX-loaded nanoparticules. Four doses of
      Investigational Product (IP) will be administered, once per week.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study will be divided in 3 phases:
Phase A: subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
Phase B: will only start after 2nd or 3rd administration of phase A. Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
Phase C: will only start after 2nd or 3rd administration of phase B. Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in clinical conditions</measure>
    <time_frame>21 days</time_frame>
    <description>Clinical condition will be measured by lung injuries</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Clinical symptoms - respiratory rate</measure>
    <time_frame>21 days</time_frame>
    <description>Evaluation of Pneumonia change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoxia</measure>
    <time_frame>21 days</time_frame>
    <description>oxygen saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of blood oxygen</measure>
    <time_frame>21 days</time_frame>
    <description>PaO2 / FiO2 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory parameters</measure>
    <time_frame>21 days</time_frame>
    <description>C-reactive protein and ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Acute Respiratory Syndrome</measure>
    <time_frame>21 days</time_frame>
    <description>Time to wean off oxygen invasive ventilatory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital discharge</measure>
    <time_frame>21 dyas</time_frame>
    <description>Time to be discharged from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU discharge</measure>
    <time_frame>21 days</time_frame>
    <description>Time to be discharged from ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of mortality</measure>
    <time_frame>4 months</time_frame>
    <description>Evaluation of change in acute respiratory syndrome</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase A: subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase B: will only start after 2nd or 3rd administration of phase A. Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase C: will only start after 2nd or 3rd administration of phase B. Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Phase A: Subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).</description>
    <arm_group_label>A</arm_group_label>
    <other_name>MTX-loaded nanoparticles</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Phase B: Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).</description>
    <arm_group_label>B</arm_group_label>
    <other_name>MTX-loaded nanoparticles</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Phase C: Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).</description>
    <arm_group_label>C</arm_group_label>
    <other_name>MTX-loaded nanoparticles</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent from patient or legal representative.

          2. Male or female, aged ≥ 18 years;

          3. Acute respiratory distress syndrome; with imminent risk of death, and with chest CT
             scan with pulmonary impairment greater than 50%;

          4. Confirmed or pending diagnosis of COVID-19.

        Exclusion Criteria:

          1. Pleural effusion &gt; 150mL or ascites &gt; 200mL;

          2. Chronic liver disease;

          3. ALT and AST serum levels &gt;= three times the upper limit of normality;

          4. Renal failure (dialysis)

          5. Multiple organ failure

        7. Concomitant use or use in the last 7 days of cell therapy with stem cells; 8. Any
        clinical or laboratory condition or comorbidity that, at medical discretion, 9. Known
        hypersensitivity to the investigational product; 10. Subject who is pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rodrido Esper, MD, PhD</last_name>
    <phone>+55 11 98179-7949</phone>
    <email>dr.rodrigo.esper@preventsenior.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luciana Ferrara</last_name>
    <phone>+55 19 981428814</phone>
    <email>luciana.ferrara@azidusbrasil.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prevent Senior Private Operadora de Saúde LTDA.</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Rodrigo Barbosa Esper</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

